{"id":"vinorelbine-bitartrate","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Neuropathy (peripheral)"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"25-35","effect":"Fatigue"},{"rate":"20-30","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL553025","moleculeType":"Small molecule","molecularWeight":"778.95"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Vinorelbine bitartrate binds to β-tubulin and prevents microtubule polymerization, which disrupts the mitotic spindle formation necessary for cell division. This leads to cell cycle arrest in the G2/M phase and triggers programmed cell death in rapidly dividing cancer cells. The bitartrate salt form improves solubility and bioavailability compared to the free base.","oneSentence":"Vinorelbine bitartrate is a semi-synthetic vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:34.853Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT06107790","phase":"PHASE3","title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2018-05-16","conditions":"HER2-positive Breast Cancer","enrollment":570},{"nctId":"NCT02223611","phase":"PHASE2","title":"Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer Stage Ⅱ, Non-small Cell Lung Cancer Stage ⅢA","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vinorelbine Bitartrate","genericName":"Vinorelbine Bitartrate","companyName":"Zhejiang Hisun Pharmaceutical Co. Ltd.","companyId":"zhejiang-hisun-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vinorelbine bitartrate is a semi-synthetic vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in cancer cells. Used for Non-small cell lung cancer (NSCLC), Breast cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}